Key result
UCL2077 potently inhibits Kv7.1 channels via state-dependent open-channel block with ~70 pM potency.
Why the study?
Gain-of-function mutations in Kv7.1 or KCNE1 cause short QT syndrome, making the study of pharmacological inhibitors of Kv7.1 and IKs of therapeutic interest.
Effect estimate: IC50 70 pM (95% CI 44-113 pM)
UCL2077 acts as a highly potent, state-dependent open-channel inhibitor of Kv7.1 and IKs, providing valuable insights for developing channel modulators in the context of Short QT Syndrome.
In cardiomyocytes, Kv7.1 associates with the regulatory subunit KCNE1 to generate the delayed rectifier potassium current I Ks , which plays a crucial role in cardiac repolarization at elevated heart rates. Gain-of-function mutations in either of these subunits are associated with short QT syndrome (SQTS), a condition that increases the risk of cardiac arrhythmias including atrial fibrillation, syncope and sudden death. Therefore, the study of pharmacological inhibitors of Kv7.1 and I Ks is of significant therapeutic interest. In this work, we used whole-cell patch clamp recordings to characterize the electrophysiological effects of the Kv7.1 blocker 3-(triphenylmethylaminomethyl)pyridine (UCL2077) in both Kv7.1 and I Ks (Kv7.1 + KCNE1) channels. We found that UCL2077 inhibited both Kv7.1 and I Ks channels with high affinity (IC 50 in the picomolar range) and mild voltage-dependence. The drug induced a biphasic time-dependent current decay and reduced current reactivation of Kv7.1, while the kinetics of I Ks were unaffected. We examined state-dependence using mutations that functionally stabilize Kv7.1/ I Ks in either the intermediate-open (IO; E160R/R231E) or in the activated-open (AO; E160R/R237E) state. In both channels, UCL2077 potency correlated with the strength of the electromechanical coupling. Our results are further supported by a kinetic Markov model simulating UCL2077 binding that closely resembles the experimental currents. Overall, our work provides an in-depth characterization of UCL2077's action on Kv7.1 and I Ks channels, offering valuable insights for the development of Kv7.1/ I Ks inhibitors in the context of short QT syndrome and other cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Sastre et al. (2025) studied Kv7.1 and IKs channel function (Short QT syndrome context). UCL2077 vs. Control (absence of UCL2077) was evaluated on Inhibition of Kv7.1 channels (IC50 at tail currents) (IC50 70 pM, 95% CI 44-113 pM). UCL2077 potently inhibited Kv7.1 channels with an IC50 of 70 pM at tail currents, demonstrating high-affinity, state-dependent open-channel block.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: